



18 February 2016

FULLY UNDERWRITTEN RIGHTS ISSUE

Highlights

- 2 for 1 rights issue at 0.5 cents to raise ~ \$1.85 million
- Funds to be used for acquisition of 24.53% interest in Omniblend Innovation
- Issue is fully underwritten and was heavily oversubscribed
- Ex-rights date will be 23 February 2016

EVE Investments Limited (ASX:EVE) (EVE Investments or the Company), an ASX-listed technology investment company, is pleased to announce a fully underwritten non-renounceable rights issue to fund the initial acquisition of a 24.53% interest in Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE is acquiring up to a 39.39% interest, subject to certain conditions (see ASX announcement on 17 December 2015).

EVE has completed to its satisfaction due diligence on Omniblend Innovation. Completion of the first tranche subscription (by EVE Investments paying \$1,625,000 for a 24.53% interest in Omniblend Innovation) has been extended by mutual agreement to 31 March 2016 to coincide with completion of the rights issue. The outstanding condition precedent to be satisfied or waived is EVE Investments, Omniblend Innovation and its current shareholders agreeing shareholders agreement terms. The parties are currently seeking to finalise this agreement.

EVE Investments is offering 1 new share ("New Share") for every 2 shares held at an issue price of 0.5 cents per New Share to raise approximately \$1,859,167 through the issue of approximately 371,833,362 shares. The prospectus for the rights issue will be lodged by the Company today. CPS Capital Group Pty Ltd acts as Lead Manager and the Underwriter. The Company is pleased with the strong level of interest shown to date, with the underwriting closing heavily oversubscribed.

The net proceeds from the rights issue will be used (with existing cash) to fund the first tranche of the Omniblend Innovation subscription. In addition, the funds will be used for the identification and evaluation of further technology investment opportunities for the Company and for working capital.

The timetable for the Offer is as follows:

| | Lodgement of Prospectus with ASIC and ASX | 18 February 2016 |
|----|---|------------------|
|)) | Notice (letter) to Shareholders | 22 February 2016 |
| | Ex date | 23 February 2016 |
| | (date from which shares commence trading without the entitlement to | |
| | participate in the Offer). | |
| | Record Date | 25 February 2016 |
| | (date for identifying Shareholders entitled to participate in the Offer). | |
| | Prospectus with Entitlement Form sent to Eligible Shareholders | 1 March 2016 |
| | Offer opens | 1 March 2016 |
| | Closing Date | 16 March 2016 |
| | (last date for lodgement of Entitlement Forms and Application Money) | |

| Deferred settlement trading | 17 March 2016 |
|---|---------------|
| Company to notify ASX of the Shortfall (if any) | 21 March 2016 |
| Issue date and end of deferred settlement trading | 23 March 2016 |
| Normal trading resumes | 24 March 2016 |

Subject to the Listing Rules, the above dates may be changed without notice.

Shareholders may view all the Company's ASX announcements, including those relating to the Offer on the Company's website at www.eveinvestments.com.au. Application will be made to ASX for official quotation of the New Shares. No shareholder approval is required to the Offer.

if you have any questions please do not hesitate to contact the Company.

yours faithfully

Bill Fry

Executive Director

-ENDS-

For more information:

Bill Fry
Executive Director
61 8 6465 5500
billf@eveinvestments.com.au

Justin Kelly Media & Capital Partners 0408 215 858 justin.kelly@mcpartners.com.au

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit <u>www.eveinvestments.com.au</u>